Clinical Trial Information for MBP8298
A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis
This is a two-year, randomized, double-blind, placebo-controlled, parallel-group trial in secondary progressive MS patients, comparing the time to confirmed worsening of disability as measured by EDSS (Expanded Disability Status Scale).
The trial is expected to enroll up to 553 patients. Patients will be administered either MBP8298 or ...